Gricelis Patricia Martinez

Dr. Gricelis Patricia Martinez

Universidad Central de Venezuela, Caracas, Distrito Capital, Venezuela
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Recent Patents on Inflammation & Allergy Drug Discovery
Verified
Journal Article
Open access
PDF file
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
MMMichael R. Mijares
Michael R. Mijares
Juan Bautista De SanctisJuan Bautista De Sanctis
Juan Bautista De Sanctis
Background: Various pieces of evidence have shown that people who consume foods rich in polyphenolic and flavonoids compounds have a lower incidence of inflammatory, autoimmune diseases and cancer. Objective: The study aimed to review the most potent compounds that affect the immune response and diseases associated with it. Methods: Publications in PubMed and EmBase, from 1974-2018, and patents form Free patents online, Scifinder, Espacenet and Mendeley in which flavonoids, their semi-synthetic and synthetic derivatives are involved in immunosuppressive or immunostimulatory responses in vitro and in vivo. Results: In vitro, flavonoids and their derivatives inhibit various transcriptional factors, which modulate differentiation, proliferation, activation of immune cells and enhance regulatory T cell generation. Some flavonoids exert anti-inflammatory effects through: Blockade of NF-κB, and NLRP3 inflammasome, inhibition of pro-inflammatory cytokine production, IL-1β, IL-2, IL-6, TNF-α, IL-17A, down regulation of chemokines, and reduction of reactive oxygen and nitrogen species. Nevertheless, several reports have shown that some flavonoids enhance immune response by enhancing: oxygen and nitrogen radicals, antibody production, cytotoxic activity against tumours by increasing activating receptors and down regulating inhibitory receptors. In consequence, flavonoids may be potentially useful for treatment of infectious diseases and cancer. Conclusion: The most potent flavonoids in inflammation that modify immune responses are apigenin, quercetin and Epigallocatechin-3-Gallate (EGCG) although, other compounds are still under study and cannot be excluded. The most relevant patents concerning the use of flavones and other polyphenols were revised. A promising future of these compounds in different therapies is discussed.

16 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
MZMercedes E. Zabaleta
Mercedes E. Zabaleta
CGCamilo Di Giulio
Camilo Di Giulio
Jaime CharrisJaime Charris
Jaime Charris
MMMichael Rodney Mijares
Michael Rodney Mijares
Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of the heterocyclic aromatic compound quinoline. These economical compounds have been used as antimalarial agents for many years. Currently, they are used as monotherapy or in conjunction with other therapies for the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS) and antiphospholipid antibody syndrome (APS). Based on its effects on the modulation of the autophagy process, various clinical studies suggest that CQ and HCQ could be used in combination with other chemotherapeutics for the treatment of various types of cancer. Furthermore, the antiviral effects showed against Zika, Chikungunya, and HIV are due to the annulation of endosomal/lysosomal acidification. Recently, CQ and HCQ were approved for the U.S. Food and Drug Administration (FDA) for the treatment of infected patients with the coronavirus SARSCoV- 2, causing the disease originated in December 2019, namely COVID-2019. Several mechanisms have been proposed to explain the pharmacological effects of these drugs: 1) disruption of lysosomal and endosomal pH, 2) inhibition of protein secretion/expression, 3) inhibition of antigen presentation, 4) decrease of proinflammatory cytokines, 5) inhibition of autophagy, 6) induction of apoptosis and 7) inhibition of ion channels activation. Thus, evidence has shown that these structures are leading molecules that can be modified or combined with other therapeutic agents. In this review, we will discuss the most recent findings in the mechanisms of action of CQ and HCQ in the immune system, and the use of these antimalarial drugs on diseases.

24 September 2019 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
Jaime CharrisJaime Charris
Jaime Charris
MMMelina C. Monasterios
Melina C. Monasterios
MAMaría E. Acosta
María E. Acosta
MRMiguel A. Rodríguez
Miguel A. Rodríguez
NGNeira D. Gamboa
Neira D. Gamboa
Juan Bautista De SanctisJuan Bautista De Sanctis
Juan Bautista De Sanctis

1 June 2023 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Juan Bautista De SanctisJuan Bautista De Sanctis
Juan Bautista De Sanctis
Jaime CharrisJaime Charris
Jaime Charris
ZMZuleyma Blanco Marquez
Zuleyma Blanco Marquez
HPHegira Hegira Ramírez Padilla
Hegira Hegira Ramírez Padilla
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
MMMichael Rodney Mijares
Michael Rodney Mijares
Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumourassociated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.

4 March 2021 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
HPHegira Hegira Ramírez Padilla
Hegira Hegira Ramírez Padilla
EFEsteban Fernandez-Moreira
Esteban Fernandez-Moreira
JRJuan Rodrigues
Juan Rodrigues
SMSoriuska Mayora
Soriuska Mayora
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
Jaime CharrisJaime Charris
Jaime Charris

1 November 2019 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Gricelis Patricia MartinezGricelis Patricia Martinez
Gricelis Patricia Martinez
MMMichael Rodney Mijares
Michael Rodney Mijares
KCKatiuska Chávez
Katiuska Chávez
ASAlirica Isabel Suarez
Alirica Isabel Suarez
RCReinaldo Santi Compagnone
Reinaldo Santi Compagnone
Juan Bautista De SanctisJuan Bautista De Sanctis
Juan Bautista De Sanctis